CONNECTA Therapeutics begins Phase IIa trial of CTH120 for FXS

​CONNECTA Therapeutics has started a Phase IIa trial to assess CTH120, a neuroplasticity modulator, in adult males with fragile X syndrome.

The post CONNECTA Therapeutics begins Phase IIa trial of CTH120 for FXS appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

FDA approves Bayer’s Ambelvist contrast agent
ALK’s EURneffy secures MHRA approval for anaphylaxis treatment
Lilly reports Phase III BRUIN CLL-322 trial results for Jaypirca combo
FDA clears MSD’s Keytruda combo plus Welireg for ccRCC treatment
Fleming Initiative and Cepheid begin TRACE-CPE study on rapid CPE testing

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us